A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 2
Where in China
- Qilu Hospital of Shandong UniversityJinan, ChinaContact: Yan ShiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dizal Pharmaceuticals
- Trial code
- NCT07294365
- Record updated
- 22 January 2026
- Original description
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.Read full original descriptionShow less
A Phase 2 Study to Evaluate the Efficacy and Safety of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP)
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.
Inclusion: Male and female participants ≥ 18 years of age; Diagnosed with persistent or chronic primary ITP, and an average of two platelet counts < 30 × 10⁹/L; Have failed at least one standard treatment for ITP (glucocorticoids and/or IVIG); Adequate bone marrow reserve and organ functions; Willing to comply with contraceptive restrictions.
Exclusion: Any of previous or current treatment prohibited by protocol; Have a history of coagulation disorders other than ITP, such as disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura; Any of severe cardiac abnormalities; Active infection; Poorly controlled gastrointestinal disorder, inadequate absorption of medication or other systemic diseases; Known allergy to DZD8586 drug excipients or other chemical analogues; Have evidence of secondary causes of immune thrombocytopenia; Pregnant or breastfeeding female participants.